SG11201810777WA - Purification of multispecific antibodies - Google Patents
Purification of multispecific antibodiesInfo
- Publication number
- SG11201810777WA SG11201810777WA SG11201810777WA SG11201810777WA SG11201810777WA SG 11201810777W A SG11201810777W A SG 11201810777WA SG 11201810777W A SG11201810777W A SG 11201810777WA SG 11201810777W A SG11201810777W A SG 11201810777WA SG 11201810777W A SG11201810777W A SG 11201810777WA
- Authority
- SG
- Singapore
- Prior art keywords
- basel
- roche
- international
- hoffmann
- grenzacherstrasse
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 December 2017 (21.12.2017) WIP0 I PCT Iiiimmonits Hommiololinomolluoill (10) International Publication Number WO 2017/218977 A3 (51) International Patent Classification: CO7K 1/18 (2006.01) C07K 16/06 (2006.01) CO7K 1/22 (2006.01) C07K 16/22 (2006.01) (21) International Application Number: PCT/US2017/038007 (22) International Filing Date: 16 June 2017 (16.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/351,908 17 June 2016 (17.06.2016) US (71) Applicant (for all designated States except AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR): GENENTECH, INC. [US/US]; 1 Dna Way, South San Francisco, CA 94080-4990 (US). (71) Applicant (for all designated States except AM, AZ, BF, BJ, BW, BY, CF, CG, CI, CM, GA, GH, GM, GN, GQ, GW, KE, KG, KM, KZ, LR, LS, MD, ML, MR, MW, MZ, NA, NE, RU, RTY, SD, SL, S1V, ST, SZ, TD, TG, TJ, TM, TZ, UG, ZM, ZW): F. HOFFMANN LA-ROCHE AG [CH/CH]; Grenzacher- strasse 124, 4070 Basel (CH). (72) Inventors: GIESE, Glen; c/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080 (US). ROSENBERG, Eva; c/o F. Hoffmann La-Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). SALLIER, Bernard; c/o F. Hoff- mann La-Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). KONRAD, Susanne; c/o F. Hoffmann La-Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). KOEHN- LEIN, Wolfgang; c/o F. Hoffmann La-Roche AG, Gren- zacherstrasse 124, 4070 Basel (CH). WILLMANN, St- effen; c/o F. Hoffmann La-Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). BIALAS, Agathe; c/o F. Hoffmann La-Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). KALEAS, Kimberly; c/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080 (US). YIGZAW, Yinges; c/o Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080 (US). (54) Title: PURIFICATION OF MULTISPECIFIC ANTIBODIES FIG. 1 A. aX1 (knob) aY1 (hole) • If protein A capture chromatography (bind and elute mode) 1 protein A capture chromatography (bind and elute mode) N N cc N O C assemble purified aX1 and aY1 to form aX1/Y1 bispecific Ab multimodal cation exchange chromatography (bind and elute mode) 4, multimodal anion exchange chromatography (flow through mode) (57) : The present invention provides methods of purifying multispecific antibodies. The methods comprise the sequential steps of performing a capture chromatography, a first mixed mode chromatography and a second mixed mode chromatography. In some aspects, the invention provides compositions of multispecific antibodies, which compositions have reduced levels of one or more product-specific impurities and/or process-specific impurities. [Continued on next page] WO 2017/218977 A3 MIDEDIMOMOIDEIRMEMOOlilliOROBERE# (74) Agent: ONUFRYK, Christina et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 18 January 2018 (18.01.2018)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662351908P | 2016-06-17 | 2016-06-17 | |
PCT/US2017/038007 WO2017218977A2 (en) | 2016-06-17 | 2017-06-16 | Purification of multispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810777WA true SG11201810777WA (en) | 2018-12-28 |
Family
ID=59593150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810777WA SG11201810777WA (en) | 2016-06-17 | 2017-06-16 | Purification of multispecific antibodies |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190256556A1 (en) |
EP (1) | EP3472177A2 (en) |
JP (2) | JP2019521986A (en) |
KR (2) | KR20230113662A (en) |
CN (1) | CN109563124A (en) |
AR (1) | AR108800A1 (en) |
AU (1) | AU2017286676A1 (en) |
BR (1) | BR112018075516A2 (en) |
CA (1) | CA3026518A1 (en) |
IL (1) | IL263690B2 (en) |
MX (1) | MX2018015173A (en) |
SG (1) | SG11201810777WA (en) |
TW (1) | TWI798179B (en) |
WO (1) | WO2017218977A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | antibodies and conjugates thereof |
JP7074859B2 (en) * | 2017-12-22 | 2022-05-24 | エフ.ホフマン-ラ ロシュ アーゲー | Method of depletion of light chain mismatched antibody variants by hydrophobic interaction chromatography |
MX2020008000A (en) * | 2018-01-30 | 2021-01-08 | Exothera Sa | Protein purification process. |
WO2019149693A1 (en) * | 2018-01-30 | 2019-08-08 | Univercells S.A. | Protein purification process and platform |
CN111423512B (en) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | Multi-targeting fusion protein for blocking vascular endothelial cell growth and activating T cells and pharmaceutical composition comprising same |
CN113840625A (en) | 2019-01-29 | 2021-12-24 | 夏尔-Nps医药品有限公司 | Parathyroid hormone variants |
EP3962924A1 (en) * | 2019-05-03 | 2022-03-09 | Genentech, Inc. | Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform |
CN114026108A (en) * | 2019-06-28 | 2022-02-08 | 信达生物制药(苏州)有限公司 | Seamless continuous flow chromatography method |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021091933A1 (en) * | 2019-11-07 | 2021-05-14 | Amgen Inc. | High salt washes during cation exchange chromatography to remove product-realated impurities |
AU2021208515A1 (en) * | 2020-01-15 | 2022-08-04 | F. Hoffmann-La Roche Ag | Methods to decrease impurities from recombinant protein manufacturing processes |
CN115066258A (en) * | 2020-02-28 | 2022-09-16 | 上海药明生物技术有限公司 | Purification of bispecific antibodies |
CN115734969A (en) * | 2020-04-13 | 2023-03-03 | 上海药明生物技术有限公司 | Purification of bispecific antibodies |
CN113563469A (en) * | 2020-04-28 | 2021-10-29 | 江苏中新医药有限公司 | Method for purifying adalimumab with high recovery rate |
CN114014906B (en) * | 2020-06-24 | 2024-01-12 | 夏尔巴生物技术(苏州)有限公司 | Method for purifying hydrophobic protein by cation exchange chromatography |
CN114539416A (en) * | 2020-11-26 | 2022-05-27 | 盛禾(中国)生物制药有限公司 | Chromatographic purification process of bispecific antibody |
BR112023018268A2 (en) * | 2021-03-09 | 2023-10-31 | Japan Chem Res | METHOD FOR PRODUCING A FUSION PROTEIN |
WO2022222949A1 (en) * | 2021-04-23 | 2022-10-27 | 和铂医药(上海)有限责任公司 | Method for purifying bispecific antibody |
WO2022225060A1 (en) * | 2021-04-23 | 2022-10-27 | 協和キリン株式会社 | Method for suppressing production of degradation products |
WO2022272119A2 (en) * | 2021-06-25 | 2022-12-29 | The Board Of Trustees Of The University Of Illinois | Synthetic toolkit for plant transformation |
KR20230057280A (en) * | 2021-10-19 | 2023-04-28 | (주)알테오젠 | Purification Method for fusion proteins with IgG Fc domain |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (en) | 1978-01-06 | 1979-08-03 | David Bernard | DRYER FOR SCREEN-PRINTED SHEETS |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
ES2096590T3 (en) | 1989-06-29 | 1997-03-16 | Medarex Inc | BI-SPECIFIC REAGENTS FOR AIDS THERAPY. |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
MX9204374A (en) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION. |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69233528T2 (en) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Process for the preparation of multivalent antigen-binding proteins |
CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
DE69308573T2 (en) | 1992-08-17 | 1997-08-07 | Genentech Inc | SPECIFIC IMMUNOADHESINE |
JP3095175B2 (en) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
DK0979281T3 (en) | 1997-05-02 | 2005-11-21 | Genentech Inc | Process for the preparation of multispecific antibodies with heteromultimers and common components |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
CN101289511A (en) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | Multivalent antibodies and uses therefore |
MXPA03005273A (en) | 2000-12-14 | 2003-09-25 | Genentech Inc | Prokaryotically produced antibodies and uses thereof. |
CA2447832C (en) | 2000-12-22 | 2012-09-25 | Jamshid Tanha | Phage display libraries of human vh fragments |
JP2005289809A (en) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | Mutant heavy-chain antibody |
PT1639011E (en) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Pegylated single domain antibodies (dab) |
PL1718677T3 (en) | 2003-12-19 | 2012-09-28 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
US7750129B2 (en) * | 2004-02-27 | 2010-07-06 | Ge Healthcare Bio-Sciences Ab | Process for the purification of antibodies |
JP4948413B2 (en) | 2004-09-23 | 2012-06-06 | ジェネンテック, インコーポレイテッド | Cysteine engineered antibodies and conjugates |
CN100475965C (en) | 2005-07-22 | 2009-04-08 | 上海高科联合生物技术研发有限公司 | Method for E, coli to express lysostaphin in high efficiency via external secretion |
JP2009541275A (en) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | Production of bispecific antibodies |
DK2059533T3 (en) | 2006-08-30 | 2013-02-25 | Genentech Inc | MULTI-SPECIFIC ANTIBODIES |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
DE102008048942B4 (en) | 2008-09-25 | 2011-01-13 | Siemens Aktiengesellschaft | Arrangement with a shaft seal |
CN102369215B (en) | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
PT2417156E (en) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Trivalent, bispecific antibodies |
SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
TWI426920B (en) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
CA2796633C (en) | 2010-04-23 | 2020-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
WO2011150110A1 (en) | 2010-05-25 | 2011-12-01 | Genentech, Inc. | Methods of purifying polypeptides |
MX342235B (en) * | 2010-11-05 | 2016-09-21 | Hoffmann La Roche | Optimized method for antibody capturing by mixed mode chromatography. |
WO2013055958A1 (en) | 2011-10-11 | 2013-04-18 | Genentech, Inc. | Improved assembly of bispecific antibodies |
EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
AU2013315750B9 (en) * | 2012-09-11 | 2018-11-15 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
KR20160044023A (en) | 2013-08-19 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography |
US20160272674A1 (en) * | 2013-11-07 | 2016-09-22 | Abbvie Inc. | Isolation and purification of antibodies |
EP3116891B1 (en) * | 2014-03-10 | 2020-02-12 | Richter Gedeon Nyrt. | Immunoglobulin purification using pre-cleaning steps |
AR101262A1 (en) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | PURIFICATION PLATFORM FOR Bispecific Antibodies |
-
2017
- 2017-06-16 AU AU2017286676A patent/AU2017286676A1/en active Pending
- 2017-06-16 KR KR1020237025000A patent/KR20230113662A/en not_active Application Discontinuation
- 2017-06-16 MX MX2018015173A patent/MX2018015173A/en unknown
- 2017-06-16 AR ARP170101667A patent/AR108800A1/en unknown
- 2017-06-16 SG SG11201810777WA patent/SG11201810777WA/en unknown
- 2017-06-16 CA CA3026518A patent/CA3026518A1/en active Pending
- 2017-06-16 KR KR1020197001176A patent/KR20190039929A/en not_active IP Right Cessation
- 2017-06-16 BR BR112018075516A patent/BR112018075516A2/en unknown
- 2017-06-16 TW TW106120122A patent/TWI798179B/en active
- 2017-06-16 WO PCT/US2017/038007 patent/WO2017218977A2/en unknown
- 2017-06-16 EP EP17751870.1A patent/EP3472177A2/en active Pending
- 2017-06-16 CN CN201780047396.7A patent/CN109563124A/en active Pending
- 2017-06-16 JP JP2018565786A patent/JP2019521986A/en active Pending
-
2018
- 2018-12-13 IL IL263690A patent/IL263690B2/en unknown
- 2018-12-14 US US16/221,369 patent/US20190256556A1/en active Pending
-
2022
- 2022-07-22 JP JP2022117433A patent/JP2022166004A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017218977A8 (en) | 2019-03-28 |
AR108800A1 (en) | 2018-09-26 |
CN109563124A (en) | 2019-04-02 |
US20190256556A1 (en) | 2019-08-22 |
JP2019521986A (en) | 2019-08-08 |
AU2017286676A8 (en) | 2018-12-20 |
EP3472177A2 (en) | 2019-04-24 |
BR112018075516A2 (en) | 2019-10-01 |
KR20190039929A (en) | 2019-04-16 |
WO2017218977A3 (en) | 2018-01-18 |
IL263690B1 (en) | 2023-01-01 |
AU2017286676A1 (en) | 2018-12-13 |
JP2022166004A (en) | 2022-11-01 |
TWI798179B (en) | 2023-04-11 |
IL263690A (en) | 2019-01-31 |
CA3026518A1 (en) | 2017-12-21 |
KR20230113662A (en) | 2023-07-31 |
TW201803902A (en) | 2018-02-01 |
WO2017218977A2 (en) | 2017-12-21 |
IL263690B2 (en) | 2023-05-01 |
MX2018015173A (en) | 2019-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810777WA (en) | Purification of multispecific antibodies | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201909205YA (en) | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201807187XA (en) | Binding members to pd-l1 | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201906392WA (en) | Nucleoside-modified rna for inducing an immune response against zika virus | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof |